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ABSTRACT: Gemcitabine (GEM) is a nucleoside analogue of deoxycytidine with limited therapeutic efficacy due to enzymatic 
hydrolysis by cytidine deaminase (CDA) resulting in compromised half-life in the bloodstream and poor pharmacokinetics. To overcome 
these limitations, we have developed a methacrylate-based GEM-monomer conjugate, which was polymerized by reversible addition 
fragmentation chain transfer (RAFT) polymerization with high monomer conversion (~ 90%) and low dispersity (< 1.4). The resulting 
GEM-polymer conjugates were found to form well-defined sub-90 nm nanoparticles (NPs) in aqueous solution. Subsequently, GEM 
release was studied at different pH (~7 and ~5) with and without the presence of an enzyme, Cathepsin B. The GEM release profiles follow 
a sought-after pseudo zero-order rate and GEM-polymer conjugate NPs were prone to acidic and enzymatic degradation, following a two-
step hydrolysis mechanism. Furthermore, the NPs exhibited significant cytotoxicity in-vitro against a model pancreatic cell line. Although, 
the half-maximal inhibitory concentration (IC50) of the GEM-monomer and -polymer conjugate NPs was higher than free GEM, the 
conjugates showed superiorly prolonged activity compared to the parent drug. 
In 2014 cancers caused the death of over 163,000 people in the 
UK, of which 8,800 people died from pancreatic cancer, which 
now accounts as the fifth most lethal cancer with an estimated 
overall survival rate of 5-6%1 after 5 years. In most cases, 
pancreatic tumors are not resectable (~80%2) and hence 
chemotherapy is required. The first-line chemotherapeutic drug 
for pancreatic cancer is gemcitabine (GEM), a nucleoside 
analogue of deoxycytidine which improves the overall survival 
rate to 21% after 5 years3.  Despite its clinical potency, GEM is 
well known to be metabolically unstable due to its rapid 
deamination in the blood stream, primarily by cytidine deaminase, 
resulting in rapid clearance trough the kidneys4-5. Furthermore, its 
poor cell membrane permeability, predominantly via the human 
equilibrative type transporters (hENT1, hENT2, and hCNT36-9) 
compromises its cytotoxic activity. To compensate for these 
limitations clinically, a high dose of GEM (1,000 mg/m2) is 
administered which is often accompanied by severe side effects 
for patients such as breathlessness, neutropenia, nausea, and 
kidney failure10. In recent years, chemical derivatization of GEM 
at the 5’-OH or the primary amino position have been reported to 
formulate lipophilic or soluble GEM derivatives with interesting 
pharmacological properties that often outcompete the parent 
drug11-14. For example, the formulation of GEM (and other potent 
anticancer agents) in the form of water soluble macromolecular  
or self-assembled constructs has been shown to improve the blood 
circulation times which in turn increases their passive 
accumulation at the tumor sites via the enhanced permeation and 
retention effect15-16, protects the drugs from premature hydrolysis 
and/or deactivation and allow for further conjugation with 
targeting ligands that exert active targeting properties at the 
cellular level17-18.   
Of particular interest is the construction of polymeric prodrugs, 
where GEM is attached via a pre19, 20 or post19, 21-25 polymerization 
functionalization procedure. The latter approach is synthetically 
more accessible (see for example26), however, it often produces 
ill-defined end-products with non-quantitative drug 
functionalization or generates side-products across the polymer 
backbone. On the other hand, the synthesis of polymerizable drug 
monomers is aesthetically and practically more appealing from 
various viewpoints (i.e. polymerizable synthons allow for 
unprecedented synthetic versatility in terms of co-monomer 
combination capacity, they lead to the production of well-defined 
final polymers, and eliminate the need for further 
reaction/purification steps), and has been recently exploited in the 
synthesis of polymer-drug conjugates27-28. Different synthetic 
approaches on polymerizable GEM synthons have been reported 
in the literature. Of particular interest are the works by Kopecek et 
al.29-31 that synthesized methacrylamide-based GEM monomers 
containing an enzyme-sensitive oligopeptide linker, while Lin et 
al.32 reported the enzymatic synthesis of acrylate-based GEM 
monomers. Most recently, Xiao et al.33 reported on acrylate GEM 
derivatives with an acid-labile silyl ether bond34. Indeed, from 
these studies it is shown that it is possible to control various 
parameters such as the rate of drug loading per particle/conjugate, 
the rate of hydrolysis and the copolymerization with other 
monomers for the construction of higher-order structures. Herein 
we report a facile synthesis of a methacrylate-based GEM-
monomer conjugate that can be directly polymerized by the RAFT 
process. RAFT polymerization enables good control over the 
molecular weight and molecular weight distribution of the final 
polymer, properties that are key for bioapplications.35 In addition, 
we demonstrate that the polymer forms well-defined nanoparticles 
with very high drug loading ratio and interestingly, it exhibits 
superiorly prolonged efficacy compared to the parent drug in 
vitro.  
The GEM-monomer conjugate 3 was prepared in a direct one–
step amidation reaction by coupling GEM.HCl 1 with mono-2-
methacryloyloxy ethyl succinate 2 (Scheme 1a) at room 
temperature for 48 h  in the presence of 1-hydroxybenzotriazole 
(HOBT), 1-(3-dimethylaminopropyl)3-ethylcarbodiimide 
hydrochloride (EDC) and pyridine. The crude product was 
purified by column chromatography and was isolated in adequate 
yield of 45%. With the use of 1H-13C NMR correlation spectra 
(Figure S1) it was possible to trace the covalent linkage between 
GEM and mono-2-methacryloloxy ethyl succinate: The peak δC ~ 
172.7 ppm assigned to the carbonyl group correlates to three 
different protons δH =11.08, 2.71 and 2.59 ppm which are 
assigned to the -NH, -CH2-CH2-C(=O)-NH- and -CH2-CH2-
C(=O)-NH-  
Scheme 1. Synthesis of GEM-monomer conjugate and its 
RAFT polymerizationa   
  
a(a) Synthesis of methacrylate-based GEM-monomer conjugate 3: 
i) HOBT/EDC, pyridine, 72 h, at room temperature, DMF, under 
positive Ar (b) RAFT polymerization conditions of 3 using a 
trithiocarbonate 4 as CTA: ii) 4 h at 70 ˚C in DMF under positive 
N2 
 
groups respectively, which confirm the formation of the amide 
derivative and the complete absence of the ester side-product 
derivative (via possible attachment to the primary alcohol of 
GEM). The formation of the primary amide product was also 
confirmed by LC-MS with a found m/z value of 476.10 g/mol and 
the detection of a single signal peak on the LC spectrum which is 
indicative of the complete absence of impurities. The GEM-
monomer conjugate 3 was polymerized by RAFT at 70 ˚C, using 
(4-cyanopentanoic acid)ylethyl trithiocarbonate  chain transfer 
agent 4, and 4,4′-azobis(4-cyanovaleric acid) (ACVA) as initiator 
at a CTA/initiator ratio set to 5 (Scheme 1b) and an initial 
monomer concentration of 5 mol/L. The 1H NMR spectrum of a 
representative polymer product with degree of polymerization 
(DP) 20 is shown in Figure 1. The chemical shift δH ~ 11.04 ppm 
was assigned to the proton of the amide group, the peaks at δH ~ 
8.20 and 6.29 ppm to the protons of the methine groups of the six-
membered ring and the peaks at δH ~7.22, 6.16 and 5.24 ppm to 
the protons of the methine group of the five-membered ring of 
GEM. Furthermore, the set of peaks at the δH ranging from 4.08 to 
4.20 ppm were assigned to the protons of the methylene groups of 
the side chain (-O-CH2-) and the secondary alcohol at the 3’- 
position. Moreover, the set of peaks ranging from δH ~ 3.66 to 
3.89 ppm were assigned to the protons of the methylene group (-
CH2-OH) and the primary alcohol at the 5’-position. The peaks δH 
~ 2.71 ppm and 2.59 ppm were assigned to the protons of the 
methylene groups which are adjacent to the amide and ester group 
respectively. The broad peak at δH ~ 1.81 ppm was assigned to the 
protons of methylene group defining the methacrylate backbone 
of the polymer and the set of peaks with δH ranging from 0.78 to 
0.74 ppm were assigned to the protons of the methyl group. 
Despite the low DP of the examined polymer sample, it was not 
possible to trace the corresponding peaks of the CTA as they 
overlapped with other residues of the bulky polymer chain. 
Therefore, the Mn of the polymer could not be estimated by NMR 
spectroscopy. Furthermore, the kinetics of the RAFT 
polymerization targeting a DP of 100 repeating units was 
investigated as a model polymerization reaction (Figure 2a). The 
rate of the monomer conversion versus time was first- 
Figure 1. 1H NMR (400 MHz, DMSO-d6) spectrum of the GEM-
polymer conjugate 5; DP 20 (× designates the NMR and residual 
solvents peaks). 
order after a retardation period of 1 h. Furthermore, Mn increased 
linearly with monomer conversion (Figure 2b) although 
theoretical and experimental values were significantly different. 
For monomer conversion lower than 50%, the experimental 
values were higher than the theoretical ones whereas they were 
slightly lower than the theoretical ones for monomer conversion 
above ~ 60%. This difference can be attributed to the hybrid 
behavior of the RAFT process, that is typically observed when a 
CTA of lower chain transfer constant to the monomer (which we 
would expect for this system between the trithiocarbonate CTA 
and the bulky methacrylate GEM monomer36-37). This led to some 
uncontrolled free radical polymerization in the early stage of the 
polymerization resulting in the formation of some dead chains 
(corresponding to the shoulder observed at low conversions, 1-2h, 
Figure 2C). When the controlled system takes over, the dead 
chains are left behind and the main chain population moves to 
higher molecular weights, resulting in a lower than expected Mn, 
due to low molecular weights tail from dead chains. Eventually, 
the ĐM increased from 1.18 up to 1.36 with the increase of the 
monomer conversion. After 4 h, a monomer conversion of 90% 
was reached and a ĐM value of 1.25 was obtained. After 8 h, the 
ĐM increased to 1.4 due to termination reactions and possible loss 
of control of the polymerization. Due to this all subsequent 
polymerization times were fixed at 4 h. To investigate the 
influence of the DP on the dispersity, polymers of different chain 
lengths were prepared. DP of 10, 20 and 50 were chosen and the 
polymerization was run in DMF at 70 oC, for 4 h. A high 
monomer conversion around 90% was obtained with dispersity 
values lower than 1.2 indicating good control of the 
polymerization reaction (Figure 2d). 
Interestingly, the GEM-polymer conjugates were found to form 
well-defined NPs in aqueous suspension via a simple solvent 
evaporation process and hence the critical aggregation 
concentration (CAC) was determined using Nile red as a probe 
that emits fluorescence only in hydrophobic environments38 
(Ex.544 nm, Em.612 nm). The CAC was determined as the sharp 
fluorescence increase onset above which the polymer forms 
colloidally stable NPs (Figure S2). It was found that the CAC for 
two polymer batches with DP 20 and 100, was 0.025 and 0.007 
mM, respectively, which is indicative of the interpolymer chain-
chain type of self-assembly mechanism that is significantly more 
pronounced in the longer polymer. The average hydrodynamic 
diameter (Dh) of the GEM-polymer conjugate NPs of chain length 
of 100 repeating units was 90 ± 17 nm whereas the Dh of GEM-
polymer conjugate NPs of chain length of 20 repeating units was 
113 ± 16 nm, as determined by TEM (Figure 3). The Dhs values 
measured by DLS were 78.9 ± 13 nm and 188 ± 13 nm  
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Figure 2. Kinetics of RAFT polymerization of the GEM-
monomer conjugate; (a) pseudo first order monomer conversion 
rate, (b) evolution of Mn and ĐM as a function of the monomer 
conversion (determined by 1H NMR spectroscopy), (c) SEC traces 
of a representative GEM-polymer conjugate at different 
polymerization times for a targeted DP of 100 and (d) SEC traces 
of GEM-polymer conjugates of different chain lengths. 
 
for GEM-polymer conjugate NPs of chain length of 100 and 20 
repeating units respectively (Figure 3). The average Dh value of 
the GEM-polymer conjugate NPs of chain length of 20 repeating 
units measured by TEM was significantly lower than the value 
obtained by DLS possibly due to the dehydration of the samples 
which leads to significant decrease of the apparent size under 
TEM; presumably this effect is less observable in the polymer 
with 100 repeating units owing to the stronger chain-chain 
interpolymer interactions that lead to a more compact and 
colloidally stable nanostructure. Furthermore, the possibility of 
interparticle coagulation in suspension that could lead to higher 
Dh values should be excluded as the polydispersity (PDI) values 
by DLS were found to be 0.164 ± 0.003 and 0.069 ± 0.010 for 
GEM-polymer conjugate NPs of chain length of 100 and 20 
repeating units respectively, indicating a narrow average size 
distribution of the NPs for both polymer batches. As expected, the 
Dh of GEM-polymer conjugate NPs of chain length of 20 
repeating units were larger than GEM-polymer conjugate NPs of 
chain length of 100 repeating units, due to the more compact 
structures obtained by the larger polymer, which is in accordance 
with the lower CAC values. After 13 days in aqueous suspension, 
the average size of the NPs did not change significantly indicating 
a relatively good colloidal stability of the NPs in solution (Figure 
S3). In fact, the Dh of the GEM-polymer conjugate NPs of chain 
length of 20 repeating units decreased by only 11% after 13 days 
whereas an increase of the Dh by only 2% of the GEM-polymer 
conjugate NPs of chain length of 100 repeating units was 
observed (Figure S3). Furthermore, the PDI values were also 
similar after 13 days, indicating the maintenance of a narrow 
average size distribution of the NPs in suspension for both 
polymer batches (Figure S3).  
Next, we studied the release of GEM from the GEM-polymer 
conjugate NPs in PBS (pH 7), sodium acetate buffer (pH 5) and 
sodium acetate buffer containing Cathepsin B (pH	5) in order to 
mimic extracellular conditions (i.e. the blood plasma) and the 
intracellular acidic environment of late endosomes (Figure 4). The 
profile of GEM release from the GEM-polymer conjugate NPs of 
different chain lengths were similar indicating no influence of the 
chain length on the  
 
 
Figure 3. DLS measurements and TEM images of GEM-polymer 
conjugate NPs; DP (a) 20 and (b) 100.  
 
rate of the hydrolysis of GEM-polymer conjugate (data not 
shown). Free GEM was liberated rapidly from the dialysis tubing 
within 1 h in PBS, hence validating the dialysis method to study 
drug release. GEM was found to be released in a controlled 
manner throughout the study time in each medium, following a 
sought-after pseudo zero-order rate which was also observed in 
other drug-polymer conjugates by Convertine et al..28 The rate of 
GEM release was significantly higher at pH 5 compared to pH 7; 
in fact, 2% and 20% of GEM was released at pH 7 after 1 and 30 
days respectively, while at pH 5, 4% and 50% of GEM was 
released after 1 and 30 days, respectively. The increased rate of 
GEM release is attributed to the acidic conditions which favor the 
faster hydrolysis of the ester and the amide link of the GEM-
polymer conjugate39. Furthermore, the overall rate of GEM 
release was significantly increased with the addition of Cathepsin 
B in the sodium acetate buffer (pH 5) since approximatively, 10% 
and 70% of the drug was released from the GEM-polymer 
conjugate NPs after 1 and 30 days, respectively, which 
corroborates our hypothesis that the GEM-polymer conjugate is 
prone to enzymatic degradation, even in the absence of a 
cathepsin-specific peptide linker, as has also been shown by other 
studies12, 20-21. 
The GEM-polymer conjugate NPs were tested in vitro against a 
model pancreatic cell line (MiaPaCa-2) in order to compare their 
half-maximal inhibitory concentration (IC50) with the parent drug 
(Figure 5a).The IC50 of the latter (GEM), was found to be 450 nM 
and is consistent with values found in the literature40. The IC50 of 
the GEM-monomer conjugate was 2.5 µM which is significantly 
higher compared to the IC50 of GEM. The increase can be 
explained by the fact that GEM must be released (hydrolyzed) 
from the polymer backbone to become active. It should be noted 
that the release rate of GEM should be governed by a two-step 
hydrolysis mechanism involving an initial hydrolysis of the ester 
link followed by a second hydrolysis of the amide leading to the 
corresponding active GEM, which is the target analyte in our 
HPLC method (see ESI). As expected, similar IC50 values were 
found for the GEM-polymer conjugate NPs for two polymers 
tested; for DP 100 and 20, the IC50 values were 9.5 and 5 µM, 
respectively. These results are not surprising in that GEM is 
slowly released from the NPs and hence the effective IC50 is 
somewhat compromised compared to the parent drug. For 
example, at 72 h incubation time, approximately 16% of GEM is 
released as evidenced from the drug release curves (Figure 4). It 
should also be noted that the exact mechanism of the cytotoxic 
behaviour of the NPs is not trivial to fully elucidate  
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Figure 4. The cumulative release of GEM (%) from the GEM-
polymer conjugate (DP 20) as a function of time (days) in PBS 
(pH ~7), sodium acetate buffer (pH ~5) and sodium acetate buffer 
containing Cathepsin B (pH ~5); Data show means ±SD from 
triplicate experiments. 
 
as various factors should be considered: the cellular uptake of the 
NPs (and potentially its dependence on the average size of each 
NP batch tested), the cumulative contribution of GEM that has 
been released extracellularly and intracellularly to the overall 
cytotoxicity, as well as the possible exocytosis events that could 
take place under the tested conditions, given the prolonged 
incubation times. Therefore, we can only limit our analysis on a 
phenomenological perspective based on the results of the current 
study.  
 
Figure 5. MiaPaCa-2 cells’ viability studies with GEM, GEM-
monomer and -polymer conjugate NPs (a) as a function of the 
concentration of GEM, after 72 h of incubation and (b) as a 
function of the time at constant GEM concentration (0.033 mM). 
Nevertheless, we were motivated by the slow zero-order release 
profile of GEM from the NPs and decided to challenge the 
potentially sustained cytotoxic capacity of the NPs over a 
prolonged timeframe. We exposed GEM, GEM-monomer, and 
polymer conjugate NPs at MiaPaCa-2 cells continuously at 
constant concentrations (Figure S4). Each sample aliquot was 
incubated with cells for 72 hours before being transferred to 
freshly plated cells for a total duration of 30 days. It was found 
that the cytotoxic activity of native GEM against MiaPaCa-2 was 
compromised after 18 days (ca. 50% of cells survived, Figure 5) 
and was completely lost after 24 days of treatment. Strikingly, the 
activity of GEM-monomer and both polymer conjugates NPs was 
maintained against the cells even for 30 days of treatment (Figure 
5b). The prolonged activity of the conjugates is attributed to the 
slow GEM release, as previously discussed, that could potentially 
protect the drug from fast chemical degradation as the NPs could 
act as nanoscale drug depots that exhibit prolonged activity. This 
result also implies that in an in vivo setting, the NPs could 
potentially outperform their monomer counterparts due to their 
improved colloidal stability and the prolonged blood circulation 
times. 
In conclusion, our proposed formulation exhibits certain 
significant (clinical) advantages that are pragmatically 
encouraging to proceed in further trials: it is easy to synthesize 
(and potentially to scale up) and formulate sub-90 nm well-
defined nanoparticles, it exhibits very high drug loading per 
particle (> 50% w/w) and shows more prolonged cytotoxicity 
compared to the parent drug under the tested conditions. 
Therefore, we anticipate that our reported findings will pave the 
way for further in vivo studies.       
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